Voyager Therapeutics Inc (VYGR) Cut to “Sell” at Zacks Investment Research

Voyager Therapeutics Inc (NASDAQ:VYGR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, November 8th.

According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Other equities research analysts have also issued research reports about the company. Stifel Nicolaus reissued a “buy” rating and issued a $31.00 price objective (up previously from $20.00) on shares of Voyager Therapeutics in a report on Monday, October 23rd. Evercore ISI began coverage on Voyager Therapeutics in a report on Wednesday, August 16th. They issued an “outperform” rating and a $12.00 price objective for the company. Cowen Inc reissued a “buy” rating on shares of Voyager Therapeutics in a report on Tuesday, October 31st. ValuEngine lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, BidaskClub raised Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, July 13th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. Voyager Therapeutics currently has a consensus rating of “Hold” and an average price target of $26.13.

Voyager Therapeutics (VYGR) traded down $1.05 during midday trading on Wednesday, hitting $13.35. The stock had a trading volume of 406,533 shares, compared to its average volume of 242,629. Voyager Therapeutics has a 12 month low of $8.10 and a 12 month high of $25.99.

In other news, insider Bernard Ravina sold 10,980 shares of the business’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $20.33, for a total transaction of $223,223.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 38,430 shares of company stock valued at $562,890 in the last ninety days. Insiders own 8.00% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of VYGR. Bank of New York Mellon Corp grew its holdings in shares of Voyager Therapeutics by 15.6% during the first quarter. Bank of New York Mellon Corp now owns 44,018 shares of the company’s stock worth $582,000 after purchasing an additional 5,952 shares in the last quarter. Wellington Management Group LLP lifted its position in Voyager Therapeutics by 17.4% in the 1st quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock worth $1,739,000 after buying an additional 19,450 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in Voyager Therapeutics by 3.7% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 28,921 shares of the company’s stock worth $383,000 after buying an additional 1,026 shares during the last quarter. Hershey Trust Co. lifted its position in Voyager Therapeutics by 163.0% in the 2nd quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock worth $129,000 after buying an additional 8,921 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in Voyager Therapeutics by 57.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock worth $106,000 after buying an additional 4,343 shares during the last quarter. 37.04% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was published by BBNS and is the property of of BBNS. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://baseballnewssource.com/markets/voyager-therapeutics-inc-vygr-cut-to-sell-at-zacks-investment-research/1766934.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.